InterOcean Capital LLC reduced its stake in Allergan plc (NYSE:AGN) by 37.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,003 shares of the company’s stock after selling 4,245 shares during the quarter. InterOcean Capital LLC’s holdings in Allergan were worth $1,168,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Summit Trail Advisors LLC raised its position in Allergan by 13,646.4% during the 1st quarter. Summit Trail Advisors LLC now owns 1,199,371 shares of the company’s stock worth $1,199,000 after buying an additional 1,190,646 shares during the last quarter. Edgewood Management LLC raised its position in Allergan by 24.3% during the 1st quarter. Edgewood Management LLC now owns 5,584,109 shares of the company’s stock worth $939,750,000 after buying an additional 1,092,584 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its position in Allergan by 3,032.4% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock worth $146,337,000 after buying an additional 849,719 shares during the last quarter. Renaissance Technologies LLC raised its position in Allergan by 27,066.5% during the 2nd quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock worth $131,347,000 after buying an additional 784,928 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Allergan by 16.3% during the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after buying an additional 668,343 shares during the last quarter. 77.37% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Joseph H. Boccuzi acquired 900 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were acquired at an average price of $190.59 per share, with a total value of $171,531.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was bought at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.36% of the stock is owned by company insiders.

A number of equities analysts have issued reports on the stock. Morgan Stanley set a $202.00 price target on shares of Allergan and gave the stock an “overweight” rating in a research report on Thursday, August 23rd. Wells Fargo & Co set a $232.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a research report on Monday, August 20th. Cantor Fitzgerald set a $180.00 price target on shares of Allergan and gave the stock a “hold” rating in a research report on Monday, August 6th. Finally, Mizuho raised shares of Allergan from a “neutral” rating to a “buy” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company. Allergan has a consensus rating of “Buy” and an average price target of $210.10.

Shares of NYSE AGN opened at $190.24 on Friday. The company has a market cap of $64.66 billion, a PE ratio of 11.64, a PEG ratio of 1.46 and a beta of 1.21. Allergan plc has a 12 month low of $142.81 and a 12 month high of $237.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.85 and a current ratio of 1.00.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Thursday, July 26th. The company reported $4.42 EPS for the quarter, topping analysts’ consensus estimates of $4.13 by $0.29. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the company earned $4.02 EPS. analysts forecast that Allergan plc will post 16.29 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 17th. Stockholders of record on Friday, August 17th will be paid a dividend of $0.72 per share. The ex-dividend date is Thursday, August 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.51%. Allergan’s payout ratio is 17.61%.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Read More: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.